Blog Posts

A Program in Wonders and the Technology of Miracles

Posted by stephen005 on September 19, 2024 at 4:16am 0 Comments

At its primary, A Course in Wonders is just a channeled function, and their beginnings are shrouded in mystery. Helen Schucman, a scientific psychologist, and Bill Thetford, a research psychiatrist, worked in the 1960s to transcribe the internal dictations that Schucman stated to receive from an inner style she identified as Jesus Christ. The process of obtaining and taking these messages spanned seven years and led to the three-volume book known as A Program in Miracles.



The Text is… Continue

GCC 2G Disposables: A Comprehensive Guide to Next-Gen Vaping

Posted by se on September 19, 2024 at 4:15am 0 Comments

In recent years, disposable vaping devices have revolutionized the vaping industry, offering a convenient, portable, and hassle-free experience for both novice and experienced users. Among the popular options in the market, GCC 2G Disposables stand out for their cutting-edge technology, sleek design, and superior performance. In this article, we explore the features, advantages, and reasons why GCC 2G Disposables are becoming a top choice for vape enthusiasts.



1. What Are GCC 2G… Continue

Betting Online in Singapore: A Comprehensive Guide to Legal and Safe Practices

Posted by 8nplay on September 19, 2024 at 4:11am 0 Comments

Online betting has become a global phenomenon, offering convenience and excitement to millions of users. In Singapore, online betting is subject to strict regulations, making it essential for users to understand the legal framework and find secure, reputable platforms for betting. This article explores the legal aspects of online betting in Singapore, tips for safe betting, and a look at some of the popular forms of online gambling.…

Continue

Lucky88 đưa tin: Aston Villa khởi đầu ấn tượng ở Champions League 2024/25

Posted by Lucky88 on September 19, 2024 at 4:10am 0 Comments

CLB Aston Villa bắt đầu cuộc phiêu lưu ở Champions League 2024/25 bằng chiến thắng 3-0 hoành tráng trên sân Young Boys. Trong khi đó, nhà cựu vô địch Juventus cũng đã đánh bại PSV với cách biệt 3-1 tại thánh địa Allianz.

Aston Villa khởi đầu như mơ với thắng lợi trước Young Boys

Aston Villa khởi đầu như mơ với thắng lợi trước Young Boys



Xem thêm:… Continue

7 Things About Mecaline in Italy You'll Kick Yourself for Not Knowing

The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.

The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a remarkably slow start for a treatment that was introduced with a $56,000 annual price tag and expectations that it would strain Medicare’s budget within a few years. Uptake has been substantially slowed by concerns among insurers, physicians and families that the drug is backed by little evidence of effectiveness while coming with significant risk of potentially serious side effects.

“It’s a huge disappointment,” said Brian Skorney, an analyst at Robert W. Baird Company.

“People have for a while talked about this being potentially the biggest drug ever,” he added. “There’s no drugs that have been successful to that extent that have really had that slow of a start.”

Wall Street analysts had forecast that the drug would bring at least $12 million in the third quarter, though expectations had been tempered after the news organization STAT reported last month that just over 100 patients had received the treatment in its first few months of availability. Biogen’s stock fell about 0.6 percent by the close of trading on Wednesday.

Biogen did not disclose how many patients received its treatment in the July-to-September quarter. In its first few weeks of availability in June, the treatment brought in $1.6 million in revenue, much of which came from stockpiled inventory. Biogen said on Wednesday that it expected Aduhelm to continue to bring in minimal revenue through the rest of this year, a damaging blow for the company, which was counting on the drug to make up for declining revenue from other products.

Biogen’s chief executive, Michel Vounatsos, told analysts that the company was “not panicking” about the low sales and continued “to believe in Aduhelm’s long-term potential.” He blamed the slow sales on a lack of clarity about the whether insurers would pay for the drug.

The federal agency that administers Medicare said in July that it was starting a monthslong review to determine whether to standardize coverage of the drug nationwide, a step that could restrict which patients receive it. A draft decision is expected in January, with a final decision by April.

Several prominent academic medical centers, including the Cleveland Clinic and Mount Sinai Health System in New York, have decided not to give the drug to patients. Several regional Blue Cross Blue Shield health plans have declined to cover it, and in August, the Department of Veterans Affairs decided not to add the drug to its formulary of available medicines.

The Food and Drug Administration decided in June to approve Aduhelm, which is given as a monthly intravenous infusion, despite conflicting clinical trial results and dissent among its reviewers and advisers. In one study that yielded Mecaline in Italy a positive result, a high dose of the drug slowed decline by 0.39 on an 18-point scale. Typically mild but potentially serious side effects like brain swelling or bleeding occurred in 40 percent of clinical trial participants.

The agency’s independent advisory panel and many outside scientists opposed the approval decision. Several members of the panel quit in protest. The F.D.A. itself later called for a federal investigation of the process that led to the approval.

Views: 1

Comment

You need to be a member of On Feet Nation to add comments!

Join On Feet Nation

© 2024   Created by PH the vintage.   Powered by

Badges  |  Report an Issue  |  Terms of Service